Author Archives: Marisa Wexler MS

Study Unravels Patterns of Pseudomonas Evolution in Infections

Pseudomonas aeruginosa, the chief bacterial agent in cystic fibrosis (CF) lung infections, follows certain characteristic patterns of evolution, a new study reveals. “A long-standing lore in the cystic fibrosis field says that each patient’s infection tells a unique story, and that Pseudomonas evolves in unpredictable ways,” Jennifer Bomberger, PhD, said…

LungFit GO Safe, Well-tolerated, Interim Trial Analysis Shows

Treatment with LungFit GO, an inhaled form of nitric oxide that can be self-administered at home, has so far been well-tolerated in a pilot clinical trial testing the investigational medication in adults with or without cystic fibrosis (CF). The ongoing trial involves patients with lung infections caused by…

CF Trust, CF Foundation Launch Gene-editing Project

The U.K. Cystic Fibrosis Trust, in collaboration with the U.S. Cystic Fibrosis Foundation, is launching a new strategic research center (SRC) dedicated to studying gene editing as a potential treatment strategy for cystic fibrosis (CF). “Making gene editing a reality for people with CF will take the…

Change in CF Treatment Patterns in UK Seen With Use of Kalydeco

Since the introduction of Kalydeco (ivacaftor) in the U.K., marked changes in treatment patterns for cystic fibrosis (CF) patients using the medication have become noticeable over time, a study reported. Specifically, people treated with Kalydeco were less likely to continue with other treatments, such as inhaled antibiotics or…

Epicore Launches Wearable Patch to Analyze Sweat of CF Patients

Epicore Biosystems has launched in the U.S. a wearable patch allowing it to collect and analyze sweat for biomarker research, the company announced. Called the Discovery Patch Sweat Collection System, it may be useful in monitoring changes in sweat chloride in people with cystic fibrosis (CF), among other applications.